1
|
Katayama K, Yuichi M, Ito H. AB0391 ANALYSIS OF CLINICAL IMPROVEMENT BY 5 JAK INHIBITORS AGAINST JAK INHIBITOR iR RA PATIENTS IN JAPANESE CLINICAL PRACTICE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundRecently, Eular recommended different mode of therapeutic tool to get clinical remission. JAK inhibitors are considered to be one of candidates. Several JAK inhibitors have been used, however there are almost little informations about selection of JAK Inhibitors, especially, informations about secondary JAK for JAK inhibitor iR RA patients.ObjectivesTo analyze clinical response by second JAK inhibitors against JAK inhibitor iR RA patientsin in clinical practice.MethodsIn Japan, five JAK inhibitors have been mainly used in MTX iR or biologics iR patients from 2013 (tofacitinib, JAK1,3), 2017 (baricitinib, JAK 1,2), 2019 (Peficitinib, Pan JAK, in Asia, Japan), 2020,April (upadacitinib, JAK1,2, mainly JAK1) and 2020.Nov (filgotinib, JAK1). In our clinic, these JAK inhibitors were sequentially used to get clinical remission. Numbers of patients who used JAK inhibitors are 28 patients in tofacitinib, 38 patients in baricitinib, 27 patients in peficitinib, 34 patients in upadacitinib, and 13 patients in filgotinib. Among them, 22 JAK inhibitor iR RA patients were investigated for clinical effectiveness.ResultsSummery of study were shown in Tables 1 and 2. Biologics were used in 14 patients and satisfied D2T RA (1st row, green color). For pre JAK inhibitors, 12 tofacitinib, 6 baricitinib, 4 peficitinib have been used. JAK inhibitor for JAK inhibitor iR patients, 13 upadacitinib, 3 baricitinib, 3 peficitinib and 3 filgotinib were used. Six months later, 9/13 patients in upadacitinib, 2/3 in filgotinib, 2/3 in peficitinib, 0/3 in baricitinib, totally 13/22 improved clincal disease activity (Eular good+ moderate response). Clinical improvement about ACPA negative (6th row, yellow color) patients, especially RF negative (5th row, blue color) patients, are incomplete. Double negative (ACPA, RF)or RF negative may be a predicter for clinical response about 1st and successive response for upadacitinib treated patients. Since, first JAK in 4 patients (8 th row, dark green)- 3 tofacitinb, 1 baricitinib respond well firstly (secondary unresponsiveness), tofacitinib may be useful for double negative or RF negative RA patients.ConclusionJak inhibitors are useful for another JAK inhibitor iR RA patients in clinical practice. However, to get good response, baseline immunogenicity, RF/ACPA positivity, JAK specificity need to be considered. To solve, prospective clinical study may be required.ReferencesNoneDisclosure of InterestsNone declared
Collapse
|
2
|
Katayama K, Okubo T, Yujiro K, Fukai R, Sato T, Yuichi M, Abe S, Ito H. SAT0146 INHIBITION OF RADIOGRAPHIC PROGRESSION BY IGURATINOD IN 116 JAPANESE RHEUMATOID ARTHIRITIS PATIENTS DESPITE CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS THERAPY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Japanese double-blind clinical practice studies of Iguratimod (IGU) for active rheumatoid arthritis (RA) patients indicated an early and sustained efficacy as a new conventional synthetic disease-modyfing anti-rheumatic drugs (csDMARDs) [1] as well as the safety of the treatment[2]. IGU also inhibit activation of NFkB and production of RANKL, indicating strong inhibiting activity against bone destruction. However, studies focused on the inhibitory effects of joint destruction by IGU has been poorly documented in clinical practice (3).Objectives:To evaluate inhibitory effect during 1 year by additional IGU therapy in 116 RA patients despite csDMARDs therapy.Methods:Inhibitory effects of joint damage were evaluated by modified total Sharp scoring (mTSS) at baseline and 1 year after IGU prescription. RA activity was measured by DAS28-ESR.Results:The subjects were 116 cases, 30 male, age 63.2 yrs, disease duration 93.7 months. MTX was used weekly (84 cases, 72.4%), and cs DMARDs were used as BUC 43 cases, SASP 13 cases, TAC 5 cases, and LEF 1 cases. bDMARDs were used even in 8 cases, and steroids were used in 3.9 mg (70 cases, 60.3 %). Complications were observed in 70 cases (60.3%). DAS28-ESR were significantly improved from 4.29 (baseline) to 3.65 (6 months), 3.68 (12 months), respectively (P<0.0001). As shown in Figure 1, joint destruction measured by mTSS was significantly suppressed from 7.74 to 0.57 at 1 year (P<0.0001). 70.6% of patients satisfied structural remission (ΔmTSS≤0.5). Clinically relevant radiographic progression (CRRP)(mTSS>3) was observed in 10 cases (8.6%), and rapid radiographic progression(RRP) (mTSS≥5) was observed in 2 cases (1.6%). Adverse events were observed in 26 cases (22.4 %).To investigate prognostic factor for CRRP, clinical data in baseline, 6, 12 months between ten patients with CRRP and 82 patients with structural remission were compared. As shown in Table 1, longer disease duration, more SJC (P<0.05), High CRP level(P<0.005) were prognostic for CRRP in IGU treated patients.Conclusion:Iguratimod suppressed not only clinical activities but also joint destruction in RA patients resistant to csDMARDs therapy.Table 1. Prognostic factor for CRRPReferences:[1]Ishiguro N, Yamamoto K, Katayama K et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2013;23(3):430-9[2]Hara M, Ishiguro N, Katayama K et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-level extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2014;24(3):410–8.[3]Ishikawa K, Ishikawa J.Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-jB and production of RANKL: Its efficacy, radiographic changes,safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients. Mod.Rheumatol.2019,29(3), 418–429.Disclosure of Interests:None declared
Collapse
|
3
|
Katayama K, Yujiro K, Okubo T, Fukai R, Sato T, Yuichi M, Abe S, Ito H. FRI0127 Suppression of radiographic progression after gradual methotrexate tapering in patients with rheumatoid arthritis patients maintaining low disease activity - Prospective multicenter study-. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Many studies have been reported to reduce/discontinue Biologics in the treatment of rheumatoid arthritis (RA). In contrast, study for tapering methotrexate (MTX) has been limited (1,2).Objectives:We prospectively examined whether bone destruction will progress at 48 weeks after tapering or discontinuing MTX (UMIN000028875).Methods:The subjects were RA patients who have maintained low disease activity or lower for 24 weeks or more in DAS28-CRP after MTX administration. Patients having PDUS Grade 2 or 3 per site by bilateral hand ultrasonography (26 area) were excluded in this study owing to risk for joint destruction. The joint destruction was evaluated by the joint X-ray evaluation by modified total Sharp scoring (mTSS) at 1 year after the start of tapering MTX. Evaluation of clinical disease activities, severe adverse events, the continuation rate during MTX tapering were also evaluated. According to tapering response, prognostic factor for good response for tapering, joint destruction was determined. Predictors for successful tapering MTX and progression of bone destruction were determined. Statistical analysis was performed by t-test or Wilcoxon rank sum test using SAS .13.2 software.Results:The subjects were 79 (16 males, 63 females). Age average 60.9 years, disease duration 4 years 4 months, MTX dose 8.43 mg / w, DAS28-CRP 1.52, DMARDs (24.3%), ACPA 192.7 U / ml (70.5%), RF 55.6 IU / ml (65.4%).MTX was tapered from an average of 8.43 mg / w before study to 5.46 mg / w one year later. In the treatment evaluation, DAS28-CRP increased from 1.52 to 1.84. 89.7% of subjects did not progress joint damage. Other disease activities significantly increased (Table 1). The one-year continuation rate was 78.2%. Since tapering effects were varied widely, we divided patients into three groups; Flared group (N=14, initial MTX dose 8.71mg/w, final MTX dose 8.42mg/w), Low response group (N=31, final MTX reduction rate< 50%, initial MTX dose 8.93mg/w, final MTX dose 6.22mg/w), High response group (N=34, final MTX reduction rate≥ 50%, initial MTX dose 8.5mg/w, final MTX dose 3.15mg/w)(Table 2).Higher RF value at baseline and higher MTX dose at 3M, 6M were predictors of whether a subject was in Low response group or High Response group. Higher RF value and mTSS at baseline and higher MTX dose at 6M were predictors whether a subject was in Flared group or High response group. Lower age was predictor of whether a subject was in Flared group or Low responder group. Finally, mean ΔmTSS /y in Flared group (0.36) was not significantly higher than in low response group (0.07) and in high response group (0.01).Table 1Table 2.Predictors for successful tapering MTX and progression of bone destructionConclusion:Patients with MTX-administered low disease activity and finger joint echo PDUS grade 1 satisfy almost no joint destruction even after MTX reduction. For tapering, predictors may be helpful for maintaining patient’s satisfaction.References:[1]Baker KF, Skelton AJ, Lendrem DW et al. Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study. J. Autoimmunity. 2019;105: 102298.[2]Lillegraven S, Sundlisater N, Aga A et al. Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial. American College of Rheumatology. 2019; Abstract L08.Disclosure of Interests:None declared
Collapse
|
4
|
Katayama K, Okubo T, Sato T, Fukai R, Yuichi M, Yujiro K, Ito H. AB0298 LONG-TERM SUPPRESSION OF RAPID RADIOGRAPHIC PROGRESSION AFTER DISCONTINUATION/REDUCTION OF SHORT-TERM BIOLOGIC THERAPY IN PATIENTS WITH EARLY DESTRUCTIVE RHEUMATOID ARTHRITIS ACCOMPANIED WITH EXTENSIVE BONE MARROW EDEMA. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:We reported that short-term (3 or 6 months) treatment with biologics (BIO) group compared with conventional synthetic non-biological disease-modifying anti rheumatic drug (csDMARDs) enhanced group is more effective in the reducing bone marrow edema (BE) and improving structural remission in early destructive RA accompanied with extensive hand BM despite csDMARDs therapy (1).Objectives:Purpose of this extended study is to investigate whether suppression of RRP will maintain after the discontinuation/reduction of short term biological treatment during over 1 year. Clinical registration number; (UMIN-CTR 000013614)(Figure 1)Methods:RA disease activity was evaluated by DAS28-ESR after BIO withdrawal/reduction at 12 months. Bone destruction was determined by modified total Sharp scoring (mTSS) using by conventional radiography expressed as yearly progression of mTSS (ΔmTSS/y) at 12 months. Statistical analysis were performed by t-test or Wilcoxon rank sum test using SAS .13.2 softwareResults:Fourteen out of 23 patients in BIO group achieved improvement of BM (>70% improvement of baseline BE). Three patient continued BIO. Among 11 patient started to discontinuation/reduction of BIO, 7 patients were successful for discontinuation of BIO. Four patients flared (Table 1). Mean DAS28-ESR, mean ΔmTSS/y at 0, 12 months after discontinuation in 7 patients were 1.77, 2.02 and -0.66,-0.44, respectively (no significant difference between values in 0 and12 month). In contrast, those in 4 flared patients were 1.91, 4.08 and 0, 1.83, respectively (significant difference). Finally, to resolve baseline prognostic factors for improvement of BE for biological treatment, we compared baseline data between 14 BE improved and 9 BE unimproved RA patients. Low DAS28-ESR at 3 or 6 month (P<0.001) are indicated for significant prognostic factor for improvement of BE, although Low DAS28-ESR at baseline (P=0.07) may associate improvement of BE.Table 1.Summary of 1 year clinical data in 11 patients treated in BIO discontinuation/reduction after improvement of BE by short-term treatment of BIOConclusion:Results of this study indicated suppression of RRP will maintain during over 1 year after the discontinuation of short term biological treatment in some patients. We recommend that a short-term treatment with biologics for early RA patients, who are resistant to non-bio DMARDs therapy and at high risk to transit to RRP, will be an effective and economical treatment strategy.References:[1]K. Katayama, T. Okubo, S. Sato et al. Prevention of extensive bone marrow edema and consequent rapid radiographic progression by short term usage of biologics in DMARDs resistant patients with early destructive rheumatoid arthritis. EULAR meeting. FRI 0124(2018).Disclosure of Interests:None declared
Collapse
|
5
|
Bisschops R, East JE, Hassan C, Hazewinkel Y, Kamiński MF, Neumann H, Pellisé M, Antonelli G, Bustamante Balen M, Coron E, Cortas G, Iacucci M, Yuichi M, Longcroft-Wheaton G, Mouzyka S, Pilonis N, Puig I, van Hooft JE, Dekker E. Correction: Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy 2019; 51:C6. [PMID: 31853914 DOI: 10.1055/a-1074-5788] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Raf Bisschops
- University Hospitals Leuven, Department of Gastroenterology and Hepatology, TARGID, KU Leuven, Belgium
| | - James E East
- Translational Gastroenterology Unit, Nuffield Department of Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford, UK.,Oxford National Institute for Health Research Biomedical Research Centre, Oxford, UK
| | - Cesare Hassan
- Digestive Endoscopy Unit, Nuovo Regina Margherita Hospital, Rome, Italy
| | - Yark Hazewinkel
- Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Michał F Kamiński
- Department of Gastroenterological Oncology, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.,Department of Gastroenterology, Hepatology and Oncology, Medical Center for Postgraduate Education, Warsaw, Poland.,Institute of Health and Society, University of Oslo, Oslo, Norway
| | - Helmut Neumann
- Department of Medicine I, University Medical Center Mainz, Mainz, Germany
| | - Maria Pellisé
- Department of Gastroenterology. Institut Clinic de Malalties Digestives I Metabòliques, Hospital Clinic of Barcelona, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
| | - Giulio Antonelli
- Endoscopy Unit, Sant'Andrea University Hospital, "Sapienza" University of Rome, Rome, Italy
| | - Marco Bustamante Balen
- Gastrointestinal Endoscopy Unit, Digestive Diseases Department, La Fe Polytechnic University Hospital, Valencia, Spain.,Gastrointestinal Endoscopy Research Group, La Fe Health Research Institute, Valencia, Spain
| | - Emmanuel Coron
- CHU Nantes, Université Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Nantes, France
| | - Georges Cortas
- Division of Gastroenterology, University of Balamand Faculty of Medicine, St. George Hospital University Medical Center, Beirut, Lebanon
| | - Marietta Iacucci
- Institute of Translational of Medicine, Institute of Immunology and Immunotherapy and NIHR Biomedical Research Centre, University of Birmingham and University Hospitals, Birmingham NHS Foundation Trust, UK
| | - Mori Yuichi
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
| | | | - Serguei Mouzyka
- National Medical Academy of Postgraduate Education, Kyiv, Ukraine
| | - Nastazja Pilonis
- Department of Gastroenterological Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.,Department of Gastroenterology, Hepatology and Oncology, Medical Center for Postgraduate Education, Warsaw, Poland
| | - Ignasi Puig
- Digestive Diseases Department, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain.,Department of Medicine, Facultat de Ciències de la Salut, Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Manresa, Spain
| | - Jeanin E van Hooft
- Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Evelien Dekker
- Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, The Netherlands
| |
Collapse
|
6
|
Bisschops R, East JE, Hassan C, Hazewinkel Y, Kamiński MF, Neumann H, Pellisé M, Antonelli G, Bustamante Balen M, Coron E, Cortas G, Iacucci M, Yuichi M, Longcroft-Wheaton G, Mouzyka S, Pilonis N, Puig I, van Hooft JE, Dekker E. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy 2019; 51:1155-1179. [PMID: 31711241 DOI: 10.1055/a-1031-7657] [Citation(s) in RCA: 187] [Impact Index Per Article: 37.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
1: ESGE suggests that high definition endoscopy, and dye or virtual chromoendoscopy, as well as add-on devices, can be used in average risk patients to increase the endoscopist's adenoma detection rate. However, their routine use must be balanced against costs and practical considerations.Weak recommendation, high quality evidence. 2: ESGE recommends the routine use of high definition systems in individuals with Lynch syndrome.Strong recommendation, high quality evidence. 3: ESGE recommends the routine use, with targeted biopsies, of dye-based pancolonic chromoendoscopy or virtual chromoendoscopy for neoplasia surveillance in patients with long-standing colitis.Strong recommendation, moderate quality evidence. 4: ESGE suggests that virtual chromoendoscopy and dye-based chromoendoscopy can be used, under strictly controlled conditions, for real-time optical diagnosis of diminutive (≤ 5 mm) colorectal polyps and can replace histopathological diagnosis. The optical diagnosis has to be reported using validated scales, must be adequately photodocumented, and can be performed only by experienced endoscopists who are adequately trained, as defined in the ESGE curriculum, and audited.Weak recommendation, high quality evidence. 5: ESGE recommends the use of high definition white-light endoscopy in combination with (virtual) chromoendoscopy to predict the presence and depth of any submucosal invasion in nonpedunculated colorectal polyps prior to any treatment. Strong recommendation, moderate quality evidence. 6: ESGE recommends the use of virtual or dye-based chromoendoscopy in addition to white-light endoscopy for the detection of residual neoplasia at a piecemeal polypectomy scar site. Strong recommendation, moderate quality evidence. 7: ESGE suggests the possible incorporation of computer-aided diagnosis (detection and characterization of lesions) to colonoscopy, if acceptable and reproducible accuracy for colorectal neoplasia is demonstrated in high quality multicenter in vivo clinical studies. Possible significant risks with implementation, specifically endoscopist deskilling and over-reliance on artificial intelligence, unrepresentative training datasets, and hacking, need to be considered. Weak recommendation, low quality evidence.
Collapse
Affiliation(s)
- Raf Bisschops
- University Hospitals Leuven, Department of Gastroenterology and Hepatology, TARGID, KU Leuven, Belgium
| | - James E East
- Translational Gastroenterology Unit, Nuffield Department of Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford, UK.,Oxford National Institute for Health Research Biomedical Research Centre, Oxford, UK
| | - Cesare Hassan
- Digestive Endoscopy Unit, Nuovo Regina Margherita Hospital, Rome, Italy
| | - Yark Hazewinkel
- Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Michał F Kamiński
- Department of Gastroenterological Oncology, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.,Department of Gastroenterology, Hepatology and Oncology, Medical Center for Postgraduate Education, Warsaw, Poland.,Institute of Health and Society, University of Oslo, Oslo, Norway
| | - Helmut Neumann
- Department of Medicine I, University Medical Center Mainz, Mainz, Germany
| | - Maria Pellisé
- Department of Gastroenterology. Institut Clinic de Malalties Digestives I Metabòliques, Hospital Clinic of Barcelona, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
| | - Giulio Antonelli
- Endoscopy Unit, Sant'Andrea University Hospital, "Sapienza" University of Rome, Rome, Italy
| | - Marco Bustamante Balen
- Gastrointestinal Endoscopy Unit, Digestive Diseases Department, La Fe Polytechnic University Hospital, Valencia, Spain.,Gastrointestinal Endoscopy Research Group, La Fe Health Research Institute, Valencia, Spain
| | - Emmanuel Coron
- CHU Nantes, Université Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Nantes, France
| | - Georges Cortas
- Division of Gastroenterology, University of Balamand Faculty of Medicine, St. George Hospital University Medical Center, Beirut, Lebanon
| | - Marietta Iacucci
- Institute of Translational of Medicine, Institute of Immunology and Immunotherapy and NIHR Biomedical Research Centre, University of Birmingham and University Hospitals, Birmingham NHS Foundation Trust, UK
| | - Mori Yuichi
- Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
| | | | - Serguei Mouzyka
- National Medical Academy of Postgraduate Education, Kyiv, Ukraine
| | - Nastazja Pilonis
- Department of Gastroenterological Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.,Department of Gastroenterology, Hepatology and Oncology, Medical Center for Postgraduate Education, Warsaw, Poland
| | - Ignasi Puig
- Digestive Diseases Department, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain.,Department of Medicine, Facultat de Ciències de la Salut, Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Manresa, Spain
| | - Jeanin E van Hooft
- Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, The Netherlands
| | - Evelien Dekker
- Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, The Netherlands
| |
Collapse
|